Oakworth Capital Inc. continued to hold its stake in Mylan N.V. (NASDAQ:MYL) during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 4,255 shares of the company’s stock at the end of the second quarter. Oakworth Capital Inc.’s holdings in Mylan N.V. were worth $165,000 at the end of the most recent quarter.
Other large investors have also bought and sold shares of the company. Bank of The West boosted its stake in Mylan N.V. by 4.9% in the first quarter. Bank of The West now owns 72,582 shares of the company’s stock valued at $2,830,000 after buying an additional 3,360 shares during the period. Wade G W & Inc. boosted its stake in Mylan N.V. by 3.6% in the first quarter. Wade G W & Inc. now owns 6,156 shares of the company’s stock valued at $240,000 after buying an additional 213 shares during the period. Baird Financial Group Inc. boosted its stake in Mylan N.V. by 10.0% in the first quarter. Baird Financial Group Inc. now owns 756,355 shares of the company’s stock valued at $29,490,000 after buying an additional 68,967 shares during the period. Geode Capital Management LLC boosted its stake in Mylan N.V. by 9.1% in the first quarter. Geode Capital Management LLC now owns 4,519,138 shares of the company’s stock valued at $175,952,000 after buying an additional 378,296 shares during the period. Finally, Bank of Montreal Can raised its position in shares of Mylan N.V. by 70.1% in the first quarter. Bank of Montreal Can now owns 1,050,878 shares of the company’s stock valued at $40,974,000 after buying an additional 433,171 shares during the period. Institutional investors and hedge funds own 69.86% of the company’s stock.
Shares of Mylan N.V. (MYL) opened at 36.92 on Thursday. The stock’s 50 day moving average price is $38.42 and its 200 day moving average price is $39.28. The firm has a market capitalization of $19.79 billion, a P/E ratio of 36.88 and a beta of 1.27. Mylan N.V. has a 52 week low of $33.60 and a 52 week high of $50.40.
Mylan N.V. (NASDAQ:MYL) last released its earnings results on Wednesday, May 10th. The company reported $0.93 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.92 by $0.01. The firm had revenue of $2.72 billion during the quarter, compared to analyst estimates of $2.81 billion. Mylan N.V. had a net margin of 4.59% and a return on equity of 23.69%. The business’s revenue was up 24.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.76 EPS. On average, analysts predict that Mylan N.V. will post $5.16 EPS for the current fiscal year.
Several research analysts recently weighed in on the company. Zacks Investment Research raised Mylan N.V. from a “sell” rating to a “hold” rating in a research report on Tuesday. Cowen and Company reaffirmed a “market perform” rating and issued a $43.00 target price (down from $55.00) on shares of Mylan N.V. in a research report on Sunday, May 21st. Royal Bank Of Canada set a $41.00 target price on Mylan N.V. and gave the stock a “hold” rating in a research report on Sunday, July 16th. Deutsche Bank AG cut their target price on Mylan N.V. from $52.00 to $51.00 and set a “buy” rating on the stock in a research report on Tuesday, April 18th. Finally, Cantor Fitzgerald assumed coverage on Mylan N.V. in a research report on Friday, June 16th. They issued a “neutral” rating and a $41.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $51.32.
In other news, President Rajiv Malik sold 25,000 shares of the company’s stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $40.00, for a total transaction of $1,000,000.00. Following the completion of the transaction, the president now owns 799,855 shares of the company’s stock, valued at $31,994,200. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Anthony Mauro sold 10,000 shares of the company’s stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the transaction, the insider now directly owns 140,653 shares of the company’s stock, valued at approximately $5,626,120. The disclosure for this sale can be found here. 0.69% of the stock is owned by insiders.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan N.V. (NASDAQ:MYL).
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.
